Latest News & Features
Refine Search
Big Pharma
There is a general acceptance that European patent law is complicated, particularly in the area of pharmaceutical inventions. Claire Baldock looks at how the EPO approaches these inventions. 1 May 2011
Americas
There is a perfect storm brewing in the healthcare industry. Over the past few years, there has been an unprecedented rise in the trade of illicit healthcare products in the secondary market. 1 May 2011
Americas
The Canadian Federal Court of Appeal recently considered whether ‘invalid selection’ can be an independent ground for invalidating selection patents. Katie Wang looks at the implications. 1 May 2011
Asia-Pacific
An Australian legislative bill could have grave consequences for the country’s life sciences industry and, potentially, for patients as well. Tania Obranovich explains. 1 May 2011
Americas
US patent reform looks like it may finally be coming. John Pegram and Mark Ellinger explain the proposed changes. 1 May 2011
Generics
Natural products have been used to relieve a variety of diseases and conditions for millennia. 1 May 2011
Americas
Homologation (recognition of equivalence) is a useful tool for simplifying administrative processes that are repeated in different countries. Nevertheless, it is not an end in itself. 1 May 2011
Big Pharma
First instance courts in France have adopted controversial interpretations of an important Enlarged Board of Appeal decision, says Stéphane Agasse. 1 May 2011
Big Pharma
The European life sciences industry has a long history. Many of the major players trace their roots to before
the war, and often began as agricultural or chemical companies. LSIPR takes a look at the leading jurisdictions. 1 May 2011
Americas
BIO represents a broad constituency of biotechnology and life sciences companies. LSIPR talks to BIO president and CEO Jim Greenwood about patent reform, healthcare, court cases and plans for the future. 1 May 2011